Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer by Bowerman, Charles J. et al.
Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in 
Taxane-Resistant Triple-Negative Breast Cancer
Charles J. Bowerman†,||, James D. Byrne||,§, Kevin S. Chu§, Allison N. Schorzman||,Δ, 
Amanda W. KeelerΔ, Candice A. SherwoodΔ, Jillian L. Perry||, James C. Luft||,§, David B. 
Darr||, Allison M. Deal&, Mary E. Napier○, William C. Zamboni||,Δ,‡, Norman E. Sharpless||,¶,#, 
Charles M. Perou||,¶,⊥, and Joseph M. DeSimone*,†,||,§,‡,◆,□
†Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 
27515, United States
||Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel 
Hill, North Carolina 27599, United States
§Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North 
Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
ΔDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, 
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
&Lineberger Comprehensive Cancer Center Biostatistics and Clinical Data Management Core, 
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
○HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, 
United States
‡Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina at Chapel 
Hill, Chapel Hill, North Carolina 27599, United States
¶Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 
27599, United States
#Division of Hematology/Oncology, Department of Medicine, University of North Carolina at 
Chapel Hill, Chapel Hill, North Carolina 27599, United States
⊥Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 
Chapel Hill, North Carolina 27599, United States
◆Department of Pharmacology, Eshelman School of Pharmacy, University of North Carolina at 
Chapel Hill, Chapel Hill, North Carolina 27599, United States
Corresponding Author: *Phone: 1-919-9622166. Fax: 1-919-9625467. desimone@unc.edu. 
Author Contributions
C.J.B. and J.D.B contributed equally to this work.
The authors declare the following competing financial interest(s): J. M. DeSimone is a founder and maintains financial interest in 
Liquidia Technologies. M. E. Napier and A. N. Schorzman hold financial interest in Liquidia Technologies.
ORCID
Joseph M. DeSimone: 0000-0001-9521-5095
HHS Public Access
Author manuscript
Nano Lett. Author manuscript; available in PMC 2017 April 25.
Published in final edited form as:
Nano Lett. 2017 January 11; 17(1): 242–248. doi:10.1021/acs.nanolett.6b03971.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
□Department of Chemical and Biomolecular Engineering, North Carolina State University, Chapel 
Hill, North Carolina 27607, United States
Abstract
Novel treatment strategies, including nanomedicine, are needed for improving management of 
triple-negative breast cancer. Patients with triple-negative breast cancer, when considered as a 
group, have a worse outcome after chemotherapy than patients with breast cancers of other 
subtypes, a finding that reflects the intrinsically adverse prognosis associated with the disease. The 
aim of this study was to improve the efficacy of docetaxel by incorporation into a novel 
nanoparticle platform for the treatment of taxane-resistant triple-negative breast cancer. Rod-
shaped nanoparticles encapsulating docetaxel were fabricated using an imprint lithography based 
technique referred to as Particle Replication in Nonwetting Templates (PRINT). These rod-shaped 
PLGA-docetaxel nanoparticles were tested in the C3(1)-T-antigen (C3Tag) genetically engineered 
mouse model (GEMM) of breast cancer that represents the basal-like subtype of triple-negative 
breast cancer and is resistant to therapeutics from the taxane family. This GEMM recapitulates the 
genetics of the human disease and is reflective of patient outcome and, therefore, better represents 
the clinical impact of new therapeutics. Pharmacokinetic analysis showed that delivery of these 
PLGA-docetaxel nanoparticles increased docetaxel circulation time and provided similar docetaxel 
exposure to tumor compared to the clinical formulation of docetaxel, Taxotere. These PLGA-
docetaxel nanoparticles improved tumor growth inhibition and significantly increased median 
survival time. This study demonstrates the potential of nanotechnology to improve the therapeutic 
index of chemotherapies and rescue therapeutic efficacy to treat nonresponsive cancers.
Graphical abstract
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Nanomedicine has the potential to shift the paradigm for the delivery of cytotoxic agents. 
The lack of target specificity and unintended toxicities of conventional small molecule 
chemotherapies compromise the utility of this therapy as well as the patients’ quality of 
life.1 Nanoparticles are designed to alter the pharmacokinetic profiles and biodistribution of 
small molecule drugs or contrast agents in patients and enable the delivery of larger doses to 
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the intended diseased tissue in an effort to improve therapeutic index, reduce systemic 
toxicity, and/or offer better imaging signals.2,3 Currently, there are a number of clinically 
available nanomedicines, including Abraxane and Doxil, and others in clinical trials that 
have been shown to improve treatments for a variety of cancers.1,4
A key challenge to successful clinical translation of more nanomedicines for anticancer 
therapy has been defining the optimal physicochemical parameters that simultaneously 
confer molecular targeting, immune evasion, and controlled drug release.5 Understanding 
the complex interdependence of these nanoparticle parameters is particularly important for 
improving delivery efficiency to tumors.2 Using PRINT, we have previously explored the 
impact of size, shape, surface chemistry, and composition to achieve maximal tumor 
uptake.6–12 These major particle parameters have been optimized for passive tumor targeting 
in subcutaneous models of cancer.13–17
Patients with triple-negative breast cancer, when considered as a group, have a worse 
outcome after chemotherapy than patients with breast cancers of other subtypes, a finding 
that reflects the intrinsically adverse prognosis associated with the disease.18–20 
Chemoresistance has been found in greater than 50% of patients with triple-negative breast 
cancer.20 The drug resistance of triple-negative breast cancers may be altered through the 
use of engineered systems that can increase intracellular drug concentrations overwhelming 
certain resistance mechanisms.3,20,21
Here, we have engineered biodegradable nanoparticles that improve the therapeutic index of 
docetaxel by altering the pharmacokinetic profile of the drug with the goal of treating 
taxane-resistant triple-negative breast cancer. The in vivo performance of PLGA-docetaxel 
nanoparticles, including pharmacokinetic (PK) profiles, efficacy, and tolerability, was tested 
in multiple cancer models, showing significant improvement over the clinical formulation of 
docetaxel. Nanotechnology-enabled delivery of docetaxel is a promising strategy for the 
treatment of triple-negative breast cancer.
Rod-shaped PLGA-docetaxel nanoparticles fabricated using the PRINT technology had a 
hydrodynamic diameter of 215.2 ± 2.1 nm and polydispersity index values of 0.05 ± 0.01 
nm with a zeta-potential of −2.9 ± 0.2 mV, as measured by dynamic light scattering and zeta 
potential instruments. Analysis of the particles by scanning electron microscopy (SEM) 
verified that the PLGA-docetaxel nanoparticles were of defined size and shape (Figure 1A). 
Drug loading of the PLGA-docetaxel nanoparticles was 39.1 ± 3.9%, as determined over ten 
separate batches. The release rate of docetaxel from the PLGA-docetaxel nanoparticles was 
determined to be up to 100% at 24 h (Figure 1B).
The in vitro cytotoxicity of PLGA-docetaxel nanoparticles was tested against two cell lines, 
A549 and MD-MBA-231 cells. The A549 cell line was chosen because it can be directly 
established as a subcutaneous xenograft in nude mice and had been previously 
investigated.15 The MD-MBA-231 cell line was chosen because of the same K-Ras and P53 
mutations that are represented in the C3Tag GEMM. PLGA-docetaxel nanoparticles had 
equivalent cytotoxicity against the A549 cell line (IC50 3.1 nM) when compared to Taxotere 
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(IC50 2.3 nM) (Figure 1C). In the MD-MBA-231 cell line, PLGA-docetaxel nanoparticles 
had similar cytotoxicity (IC50 53.2 nM) to Taxotere (IC50 63.4 nM) (Figure 1D).
Dosing of the PLGA-docetaxel nanoparticles was then evaluated in nontumor-bearing 
female nude and FVB/NJ mice. Major dose limiting toxicities of docetaxel were determined 
by a reduction in white blood cell count (WBC), body weights, and body composition 
scores. The maximum tolerated dose (MTD) for weekly dosing of Taxotere in nude mice, as 
previously studied, was observed to be 15 mg/kg for Taxotere.15 PLGA-docetaxel 
nanoparticles dosed at 15 and 30 mg/kg docetaxel showed no loss in body weight or 
neutropenia in nude mice (Figure 2A,B). PLGA-docetaxel nanoparticles dosed at 35 mg/kg 
resulted in significant body weight loss (>20%) in two of five mice and required euthanasia. 
For FVB/NJ mice, the MTD for weekly dosing of Taxotere was 35 mg/kg.15 PLGA-
docetaxel nanoparticles were dosed at 35 and 50 mg/kg docetaxel in FVB/NJ mice, with no 
adverse events or dose-limiting toxicities after a course of five weekly doses (Figure 2C,D). 
Three of five mice dosed with 55 mg/kg of PLGA-docetaxel nanoparticle doses exhibited 
significant toxicity that required euthanasia.
Pharmacokinetic and biodistribution studies demonstrated that PLGA-docetaxel 
nanoparticles increased docetaxel plasma area under the concentration (AUC) curve and 
circulation half-life (T1/2) and had similar tumor accumulation compared to Taxotere in 
A549 xenografts (Table 1, Figure 3A,B). One caveat to the calculated AUC is that the 
concentration at t = 5 min was used, which is a time point where more unencapsulated drug 
would have left the circulation compared to encapsulated drug. A single time-point analysis 
was performed in the C3Tag GEMMs to determine docetaxel accumulation in tumor and 
plasma for PLGA-docetaxel nanoparticles compared to Taxotere at 6 h postinjection (Figure 
3C,D). The administration of PLGA-docetaxel nanoparticles resulted in a 376-fold increase 
in docetaxel plasma concentration compared to Taxotere (32.525 ± 13.703 versus 0.0865 
± 0.0078 μg docetaxel/mL plasma) (Figure 3C). In addition, delivery of PLGA-docetaxel 
nanoparticles led to an approximate 2-fold nonsignificant increase in tumor accumulation 
compared to Taxotere (9.766 ± 7.733 versus 5.729 ± 1.668 μg docetaxel/g tissue) (Figure 
3D). Overall, PLGA-docetaxel nanoparticles increased docetaxel exposure in plasma and 
provided similar docetaxel exposure in tumor compared to Taxotere.
Overall survival and tumor growth inhibition were used as metrics to determine efficacy. 
Studies in A549 xenografts were performed to validate efficacy of PLGA-docetaxel 
nanoparticles. Mice with subcutaneous A549 tumors were treated once per week for up to 6 
weeks with saline, Taxotere (15 mg/kg), and PLGA-docetaxel nanoparticles (30 mg/kg) 
(Figure 4A). PLGA-docetaxel nanoparticles improved tumor growth inhibition compared to 
saline and Taxotere (Figure 4B); however, the differences were not statistically significant. 
Mice treated with PLGA-docetaxel nanoparticles had a significantly longer median overall 
survival time (>115 days) than saline and Taxotere (23 and 41 days, respectively) (Figure 
4C).
Subsequently, efficacy of PLGA-docetaxel nanoparticles was evaluated in C3Tag GEMM. 
As C3Tag GEMMs develop multiple tumors, tumor growth for each mouse was determined 
as the sum of all tumor volumes versus time; also, the threshold to reach tumor burden 
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decreased as total number of tumors increased. Mice were treated once per week for up to 6 
weeks with saline, Taxotere (35 mg/kg), or PLGA-docetaxel nanoparticles (50 mg/kg) 
(Figure 4A). At day 18, mice treated with PLGA-docetaxel nanoparticles and Taxotere 
developed significantly less tumors than mice treated with saline (Figure 4D). Mice treated 
with PLGA-docetaxel nanoparticles showed a significant improvement in tumor growth 
inhibition compared to mice treated with saline, but no statistical difference was noted 
between the two docetaxel treatments (Figure 4E). At day 20, 83% of mice treated with 
Taxotere and 67% of mice treated with saline had reached tumor burden compared to 0% of 
mice treated with PLGA-docetaxel nanoparticles (Figure 4F). Mice treated with Taxotere 
and saline had similar median survival times of 20 and 19 days, respectively, which was 
significantly shorter than the median survival time for mice treated with PLGA-docetaxel 
nanoparticles (45 days). Overall, PLGA-docetaxel nanoparticles improved survival and 
tumor growth inhibition compared to Taxotere in the C3Tag GEMM.
Here, we demonstrated that PLGA-docetaxel nanoparticles can deliver substantial amounts 
of docetaxel to tumors. The nanoparticle treatment significantly improved tumor growth 
inhibition and survival in a taxane-resistant triple-negative breast cancer GEMM using a 
higher dose of the well-tolerated encapsulated drug. Genetically engineered mouse models 
have proven to be excellent models for recapitulating the genetics and heterogeneity of 
human tumors and highly predictive of the responsiveness to drug therapy.22,23 Our 
preclinical results suggest that nanoparticle delivery of docetaxel may potentiate the current 
treatment of triple-negative breast cancer by enhancing the drug’s therapeutic index. 
Moreover, this therapy could be used in combination with other therapies. One tremendous 
advantage would be to leverage the PRINT technology for delivery of multiple agents that 
are limited by systemic toxicity and/or drug resistance.
For patients with drug-resistant triple-negative breast cancer, nanoparticle drug delivery 
could provide a modality for overcoming resistance and increasing drug concentrations in 
tumor cells and microenvironment. The lack of known specific therapeutic targets results in 
a limited arsenal to treat triple-negative breast cancer, primarily consisting of standard 
cytotoxic chemotherapy.24–26 In the metastatic setting, triple-negative breast cancer present 
with higher rates of visceral metastases has a relatively shorter medial survival of 7–13 
months and has limited duration of response to successive lines of chemotherapy (median 
response duration of 12 weeks to first line, 9 weeks to second, and 4 weeks to third line).26 
Therefore, it is important to investigate new agents that could result in a meaningful benefit.
Looking beyond breast cancer, this platform technology can be applied to a variety of other 
cancers, including gastric, head and neck, nonsmall cell lung cancer, and prostate cancer. 
Overall, our nanoparticle therapy could potentially offer an entirely new cancer treatment.
Methods
Materials
Poly(D,L-lactide-co-glycolide) (lactide/glycolide 85:15, 0.65 dL/g inherent viscosity) 
(PLGA) was purchased from Sigma-Aldrich. Chloroform and solvents (acetonitrile and 
water) for high performance liquid chromatography (HPLC) and liquid chromatography–
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mass spectrometry/mass spectrometry (LC–MS/MS) were acquired from Fisher Scientific. 
The clinical formulation of docetaxel, Taxotere, was obtained from the University of North 
Carolina (UNC) at Chapel Hill hospital pharmacy. Poly(ethylene terephthalate) (PET) sheets 
(6″ width) were purchased from KRS plastics. Fluorocur, diameter (d) = 80 nm and height 
(h) = 320 nm (80 × 320 nm), prefabricated molds were provided by Liquidia Technologies.
Particle Fabrication and Characterization
PLGA-docetaxel nanoparticles were fabricated using a continuous roll-to-roll PRINT 
manufacturing system, as previously described.15 Briefly, a thin film of PLGA and docetaxel 
was drawn on a 6″ × 12″ sheet of PET by spreading 150 μL of a PLGA-docetaxel-
chloroform (10 mg/mL PLGA and 10 mg/mL docetaxel) solution using a #5 Mayer Rod 
(R.D. Specialties). The chloroform was evaporated using a heat gun. The PLGA-docetaxel 
film was then placed in contact with the patterned side of a mold containing 80 × 320 nm 
cavities and then passed through a heated laminator at 130 °C and 80 PSI to fill the cavities 
with polymer and drug. The mold was split from the PET sheet as they passed through the 
heated laminator. The filled side of the mold was then placed in contact with a sheet of PET 
coated with 2000 g/mol poly(vinyl alcohol) (PVOH) and passed through the heated 
laminator to transfer the particles from the mold to the PVOH-coated PET sheet. The PVOH 
was used as a transfer layer to generate a particle suspension after dissolving the PVOH with 
water. Subsequently, the mold was peeled from the PET sheet, and the particles were 
removed by passing the PVOH-coated PET sheet through motorized rollers and applying 
water to create a particle suspension. The particle suspension underwent tangential flow 
filtration (Spectrum Laboratories) to remove excess PVOH, and the particle suspension was 
then freeze-dried (Labconco). Nanoparticle size and zeta potential were determined by 
Malvern Instruments Zetasizer, and size and shape were confirmed by a Hitachi model 2–
4700 SEM. Particle concentration was determined using thermogravimetric analysis 
correcting for the supernatant (TA Instruments). Drug loadings were quantified by 
dissolving the PLGA-docetaxel nanoparticles and analyzing solutions by ultraviolet 
spectroscopy–HPLC. For drug release studies, particle solutions were placed in mini-dialysis 
units with 20 kDa molecular weight cutoff and dialyzed again 1 × PBS at 37 °C. To 
determine the percent of docetaxel released over time, the amount of docetaxel remaining 
was compared to the initial amount of docetaxel in the system.
In Vitro Cytotoxicity
A549 and MD-MBA-231 cells were purchased directly from the American Type Culture 
Collection prior to initiation of these studies. All cell-based assays were performed utilizing 
cells at passage numbers ranging from 6 to 16. A549 and MD-MBA-231 cells were seeded 
in 200 μL of media (RPI 1640 or Leibovitz’s L-15 medium (respectively) with 10% fetal 
bovine serum) at a density of 5000 cells per cm2 into a 96-well microtiter plate. Cells were 
allowed to adhere for 24 h and then incubated with PLGA-docetaxel nanoparticles and 
Taxotere at docetaxel concentrations ranging from 4 μM to 0.05 nM for 72 h at 37 °C in a 
humidified 5% CO2 atm. After the incubation period, all medium/nanoparticles were 
aspirated off cells. One hundred microliters of fresh medium was added back to cells 
followed by the addition of 100 μL of CellTiter-Glo Luminescent Cell Viability Assay 
reagent. Plates were placed on a microplate shaker for 2 min (min), then incubated at room 
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temperature for 10 min to stabilize luminescent signal. The luminescent signal was recorded 
on a SpectraMax M5 plate reader. The viability of the cells exposed to PLGA-docetaxel 
nanoparticles was expressed as a percentage of the viability of untreated cells.
Animal Studies
All in vivo studies were approved by the Institutional Animal Care and Use Committee 
(IACUC) and were in accordance with The Guide for Care and Use of Laboratory Animals, 
eighth edition. For the A549 human tumor xenografts, athymic nude-FoxN1nu female mice 
were bred in-house by the UNC Animal Core Facility. Tumor cells (5.0 × 106 cells in 200 
μL of 1 × PBS) were injected subcutaneously into the right flank of each mouse at age 5–7 
weeks. Taxane-resistant GEMMs of strain FVB/NJ carrying a transgene for C3(1)SV40 T-
antigen (C3Tag) were bred in-house.21,22 Tumor volume was calculated using the formula: 
tumor volume (mm3) = (w2 × l)/2, where w = width and l = length in mm of the tumor. Mice 
were assessed three times weekly for signs of toxicity, including body mass and body 
composition. Tumors were measured twice weekly via calipers. Mice were euthanized once 
tumor volume approached burden as defined by UNC IACUC.
Dosing Studies
The MTD of Taxotere and PLGA-docetaxel nanoparticles for a total of five weekly doses 
were determined in nontumor-bearing female nude and FVB/NJ mice. Body composition 
scores and body masses were recorded twice weekly, and observations were made of signs 
of toxicity (i.e., reduced grooming, lethargy, etc.). Mice were euthanized if body mass loss 
equaled or exceeded 20% or if they exhibited any other signs of toxicity. Fifty microliters of 
blood was collected into EDTA-coated tubes by submandibular bleeding 1 week before the 
first injection, 4 days after the first 5 injections, and 2 weeks after the blood draw following 
the fifth injection. Blood was analyzed for complete blood counts with differential using a 
blood counter (Heska’s).
PK and Biodistribution Studies
For studies in A549 xenografts, the mice were randomly assigned to the Taxotere and 
PLGA-docetaxel nanoparticle treatment groups (10 mg/kg docetaxel), with individual tumor 
volumes ranged from 40 to 253 mm3 at the time of grouping. The dose of docetaxel 
administered was based upon previously published work.15,16 Formulations were diluted to 
1 mg/mL of docetaxel with normal saline and administered via a single tail vein injection. 
Mice (n = 3, per time point) were sacrificed at 0.083, 1, 6, 24, and 72 h after a single 
injection. For studies in C3Tag GEMMs, the mice (n = 5, per group) were randomly 
assigned to the Taxotere (35 mg/kg) and PLGA-docetaxel nanoparticle (50 mg/kg) treatment 
groups. Mice were sacrificed at 6 h after dosing. In both models, blood was collected via 
terminal cardiac puncture using K3-EDTA as an anticoagulant under CO2 anesthesia and 
processed for plasma by centrifugation (1500 × g for 5 min). Plasma and tissues were placed 
in cryopreservation vials and preserved by snap freezing using liquid nitrogen. Tissues were 
stored at −80 °C until analysis by LC–MS/MS.
Docetaxel and paclitaxel stock solutions (1 mg/mL) were prepared in methanol and stored at 
−20 °C. The matrix for the standard curve and quality controls (QC) consisted of control 
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mouse plasma for all plasma samples, or control tissue homogenate for the tissue being 
analyzed. Liver homogenate was used as a surrogate matrix for tumor samples. Docetaxel 
was extracted from 50 μL of standard, QC, or unknown sample by protein precipitation with 
200 μL acetonitrile/0.1% formic acid containing 20 ng/mL paclitaxel internal standard. 
Samples were vortexed for 5 min and centrifuged at 5000 × g for 10 min at 4 °C. One 
hundred and fifty microliters of supernatant was transferred to a clean 1.5 mL tube, 
lyophilized under nitrogen, and reconstituted in 60 μL of MeOH/0.1% formic acid. Fifty 
microliters of sample was transferred to a silanized glass 96-well plate insert containing 50 
μL of ddH2O and 10 μL of sample injected for analysis by LC–MS/MS analysis.
Efficacy Studies
A549 xenografts (n = 5–7) were randomly assigned to one of three treatment arms: saline, 
Taxotere (15 mg/kg), and PLGA-docetaxel nanoparticles (30 mg/kg). Once the tumor 
volume reached ~150 mm3, weekly dosing was administered for a total of six doses or until 
reaching tumor burden (2 cm in any dimension). Mice were euthanized at day 115 after the 
first therapeutic dose, if they had not yet been euthanized.
C3Tag GEMMs (n = 5–9) were randomly assigned to one of three treatment arms: saline, 
Taxotere (35 mg/kg), and PLGA-docetaxel nanoparticles (50 mg/kg). Once tumors reached a 
palpable mass of 40–64 mm3, weekly dosing was administered for a total of six doses or 
until reaching tumor burden.
PK and Statistical Analyses
Data are expressed as means ± standard deviation. Graphs were created with GraphPad 
Prism software. Log-rank tests were used to compare survival, with analyses performed 
using SAS v9.3. PK parameters were assessed with PhoenixWinNonLin (version 6.0). 
ANOVA methods were used for comparisons of continuous values between groups. 
Unpaired t tests were used when an overall difference was detected. Unadjusted P values 
were reported for pairwise comparisons when an overall difference was detected.
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Figure 1. 
PLGA-docetaxel nanoparticles used to improve the therapeutic index of docetaxel. (A) SEM 
image of rod-shaped PLGA-docetaxel nanoparticles. (B) Release kinetics of docetaxel from 
PLGA-docetaxel nanoparticles in PBS at 37 °C. Cytotoxicity of Taxotere and PLGA-
docetaxel nanoparticles were assessed in (C) A549 and (D) MD-MBA-231 cells. Data are 
means ± standard deviations (SD).
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Figure 2. 
MTD of Taxotere and PLGA-docetaxel nanoparticles was evaluated in nontumor-bearing 
mice. (A) Weight and (B) WBC counts were evaluated in nude mice after five weekly 
injections of saline, Taxotere, or PLGA-docetaxel nanoparticles. In addition, (C) weight and 
(D) WBC counts were evaluated in FVB/NJ mice after five weekly injections of saline, 
Taxotere, and PLGA-docetaxel nanoparticles. Data are means ± SD (n = 8 animals per 
group).
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Figure 3. 
PK data for Taxotere and PLGA-docetaxel nanoparticles in A549 xenografts and C3Tag 
GEMMs. (A) Plasma and (B) tumor exposure in A549 xenograft mice after a single tail vein 
injection of Taxotere or PLGA-docetaxel nanoparticles. (C) Plasma and (D) tumor exposure 
in C3Tag GEMMs 6 h after a single tail vein injection of Taxotere or PLGA-docetaxel 
nanoparticles. Data are means ± SD (n = 3 to 5 animals per group). P values were 
determined by one-way ANOVA with unpaired t test comparing Taxotere and PLGA-
docetaxel nanoparticles.
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Figure 4. 
Efficacy of PLGA-docetaxel nanoparticles in A549 xenografts and C3Tag GEMM. (A) 
Treatment schedule for efficacy studies. Evaluation of (B) tumor growth inhibition and (C) 
survival in A549 xenografts. (D) Number of tumors, (E) tumor growth inhibition, and (F) 
survival were assessed in C3Tag GEMM. Data are means ± SD (n = 6–9 per group). P 
values were determined by one-way ANOVA with unpaired t test comparing number of 
tumors. P values were determined by log rank tests for comparing survival.
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Table 1
PK of Docetaxel Delivered through PLGA-Docetaxel Nanoparticles and Taxotere in A549 Xenograftsa
specimen parameter units
formulation
Taxotere PLGA-docetaxel nanoparticles
plasma AUC0-∞ μg/mL·h 1,227 (0–72 h) 79.192 (0–72 h)
CL mL/h/kg 8.150 0.126
Vd mL/kg 10.508 4.513
tumor AUC0-t μg/mL·h 73.222 (0–72 h) 60.858 (0–72 h)
Cmax μg/mL 0.453 0.476
Clast μg/mL 0.142 0.117
Tlast h 72 72
a
Mice were administered a single treatment of Taxotere or PLGA-docetaxel nanoparticles. Organs were collected from each animal at various 
times, and total docetaxel concentrations were analyzed. Data are means ± SD (n = 3 to 5 animals per group). The limit of docetaxel quantitation 
was 1 ng/mL.
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